A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
- E. Crawford, M. Eisenberger, P. Goodman
- Medicine, BiologyNew England Journal of Medicine
- 17 August 1989
Treatment with le uprolide and flutamide is superior to treatment with leuprolide alone in patients with advanced prostate cancer, and Symptomatic improvement was greatest during the first 12 weeks of the combined androgen blockade.
TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation
- C. Sun, A. Dobi, S. Srivastava
- Biology, MedicineOncogene
- 11 September 2008
Evaluation of the transcriptome and specific gene promoters in ERG siRNA-treated cells and investigation of gene expression signatures of human prostate tumors revealed ERG-mediated activation of C-MYC oncogene and the repression of prostate epithelial differentiation genes (PSA and SLC45A3/Prostein).
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
- M. Eisenberger, B. Blumenstein, B. Lowe
- MedicineNew England Journal of Medicine
- 8 October 1998
The addition of flutamide to bilateral orchiectomy does not result in a clinically meaningful improvement in survival among patients with metastatic prostate cancer.
Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer…
- J. Miki, B. Furusato, J. Rhim
- Biology, MedicineCancer Research
- 1 April 2007
It is shown here that human telomerase reverse transcriptase (hTERT)-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines retain stem cell properties with a CD133(+) phenotype, and immunostaining of clinical prostate specimens showed that CD133 expression was detected in a subpopulation of prostate cancer cells and corresponded to the loss of AR.
Chronic orchialgia in the pain prone patient: the clinical perspective.
- R. Costabile, M. Hahn, D. Mcleod
- MedicineJournal of Urology
- 1 December 1991
A novel androgen-regulated gene, PMEPA1, located on chromosome 20q13 exhibits high level expression in prostate.
- L. Xu, N. Shanmugam, S. Srivastava
- BiologyGenomics
- 15 June 2000
PMEPA1, along with other highly androgen-induced prostate-specific genes, has potential to serve as an androgen signaling read-out biomarker in prostate tissue.
Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells
- T. Segawa, M. Nau, S. Srivastava
- BiologyOncogene
- 12 December 2002
Intriguing linkage of the androgen signaling to ER stress responsive genes, a protective response to protein unfolding or protein damage resulting from cellular stress signals, suggests that androgens may induce such stress signals in CaP cells.
Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results.
- M. Soloway, K. Pareek, A. Puras-Baez
- MedicineJournal of Urology
- 2002
PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer.
- V. Srikantan, Z. Zou, S. Srivastava
- Biology, MedicineProceedings of the National Academy of Sciences…
- 24 October 2000
The remarkable prostate-tissue specificity and androgen-dependent expression of PCGEM1 as well as its elevated expression in a significant percentage of tumor tissues suggest specific functions of PCgEM1 in the biology and tumorigenesis of the prostate gland.
...
...